Melanoma trial updates from ASCO 2018: CheckMate 238, KEYNOTE-001/006 & COLUMBUS

Melanoma trial updates from ASCO 2018: CheckMate 238, KEYNOTE-001/006 & COLUMBUS

VJOncology

1 year
218 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, hosted an array of exciting clinical trials updates in melanoma, as discussed here by Paolo Ascierto, MD, of the National Cancer Institute of Naples, Naples, Italy. Dr Ascierto covers: the CheckMate 238 study (NCT02388906); the 5-year KEYNOTE-001 (NCT01295827) update on survial and outcomes; the 4-year KEYNOTE-006 (NCT01866319) update; and the novel combination of encorafenib plus binimetinib (COLUMBUS; NCT01909453).
Up Next Autoplay
Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
Category: Melanoma and Skin Cancer
9 Views
UVA Cancer Center 2 months
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Category: Melanoma and Skin Cancer
28 Views
UVA Cancer Center 2 months
Annual meeting of the Society for Immunotherapy of Cancer (SITC) 2019 Polynoma Presenting Interim Phase III Evidence for Its Investigational Melanoma Vaccine, Seviprotimut-L
Annual meeting of the Society for Immunotherapy of Cancer (SITC) 2019 Polynoma Presenting Interim Phase III Evidence for Its Investigational Melanoma Vaccine, Seviprotimut-L
Category: Melanoma and Skin Cancer
40 Views
Cancer-News 2 months
Dual-function Virus Designed For Killing Tumor Cells and Helping Immune Cells
Dual-function Virus Designed For Killing Tumor Cells and Helping Immune Cells
Category: Melanoma and Skin Cancer
35 Views
Cancer-News 3 months
Will the CheckMate 204 data affect clinicians?
Will the CheckMate 204 data affect clinicians?
Category: Melanoma and Skin Cancer
19 Views
moasc 4 months
CheckMate 204 Study
CheckMate 204 Study
Category: Melanoma and Skin Cancer
23 Views
moasc 4 months
Clinicians could change the way they manage their patients
Clinicians could change the way they manage their patients
Category: Melanoma and Skin Cancer
4 Views
moasc 4 months
Fixing toxic therapy
Fixing toxic therapy
Category: Melanoma and Skin Cancer
8 Views
moasc 4 months
Alternate dosing for immunotherapy
Alternate dosing for immunotherapy
Category: Melanoma and Skin Cancer
4 Views
moasc 4 months
Is this data practice changing for clinicians?
Is this data practice changing for clinicians?
Category: Melanoma and Skin Cancer
4 Views
moasc 4 months